Arkolith/Insider Trading/BMRN/Form 4

Hardy Alexander

Chief Executive Officer, DirectorBIOMARIN PHARMACEUTICAL INC (BMRN) · full profile →Form 4 · filed Mar 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2025Grant(A)44K—$0176K
Mar 14, 2025Tax withholding(F)3K$69.44$204K131K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 17, 2025Grant(A)62K—$062K

Transaction Codes

A
Grant / award
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001048477-25-000027) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML